Regulatory affairs and variations for Switzerland
The work that keeps a Swiss authorisation alive after approval: variations when your EU dossier moves, renewals every five years, product information in three languages and every letter that goes to Swissmedic in the holder's name.
What does Swiss regulatory affairs actually involve?
Swiss regulatory affairs means choosing the right authorisation procedure, building the Swiss part of a dossier, filing changes in the correct category, meeting Swissmedic deadlines and keeping the product information legally current in German, French and Italian. It is a maintenance discipline: most of the work happens after approval.
Because Switzerland is outside the EU, a change you make in the EU does not reach the Swiss authorisation automatically. Every CMC change, every safety update and every new indication needs its own Swiss filing in the right change category, with the right fee and the right supporting documents.
Which authorisation procedures exist in Switzerland?
Swissmedic offers several routes, and picking the wrong one is the most expensive mistake in a Swiss project. The choice depends on the active substance, on whether a foreign authority has already assessed the product and on how urgent the medical need is.
- Standard authorisation for a new active substance, with the full assessment by Swissmedic.
- Procedures using foreign assessment results. Art. 13 HMG obliges Swissmedic to take account of the results of an assessment by a foreign authority with comparable controls, which shortens the Swiss review when the foreign report is available and complete.
- Simplified authorisation under Art. 14 HMG for defined categories, for instance products with a known active substance or medicines for rare diseases.
- Accelerated procedures for products with a clear therapeutic advance in a serious condition.
- Work-sharing routes. Swissmedic participates in international work-sharing, so a submission coordinated with partner authorities can be reviewed in parallel.
- Changes to an existing authorisation, from simple notifications to changes requiring prior approval.
Art. 13 HMG in one sentence
If a medicine is already authorised in a country with comparable medicinal product control, Swissmedic must take the results of that assessment into account. It is not automatic recognition: you still file in Switzerland, but a complete foreign assessment report usually reduces questions and review time.
What external providers deliver in a regulatory mandate
The deliverables are documents and deadlines. You see them as a quarterly report per product plus immediate notice whenever Swissmedic writes something that needs your input.
- Regulatory strategy: procedure choice, gap analysis, fee and timeline estimate before anything is filed.
- Submission package: Swiss forms, Swiss module content, product information and labelling in three languages, electronic submission.
- Question handling: drafting and filing answers to Swissmedic's list of questions inside the deadline.
- Variation management: change classification, dossier updates, artwork consequences, fee handling.
- Renewals: the five-year renewal prepared and filed in good time before expiry.
- Life cycle documentation: a Swiss change log per product that an inspector can follow.
| Document | Audience | Languages |
|---|---|---|
| Fachinformation | Healthcare professionals | German, French, Italian |
| Patienteninformation | Patients | German, French, Italian |
| Outer and inner labelling | Dispensing and traceability | German, French, Italian |
| Dispensing category wording | Pharmacy and drugstore level | As approved by Swissmedic |
Renewals, annual fees and the five-year rhythm
A Swissmedic authorisation is granted for five years and must be renewed before it expires. Renewal is not a formality: Swissmedic expects a current dossier, current product information and evidence that the safety profile has been monitored. Miss the window and you risk the authorisation lapsing, which means a new application.
On top of that there is an annual fee per authorisation. External providers diary both, pay them and report them, so the two most avoidable ways to lose a Swiss authorisation, a missed renewal and an unpaid fee, cannot happen on their watch.
Dispensing categories and what they change for you
Swissmedic assigns every medicine a dispensing category, the Abgabekategorie. It decides where the product may be sold, who may hand it over and how you may communicate about it. Since the 2019 revision the categories are A and B for prescription products, D for sale in pharmacies and drugstores with advice, and E for general sale.
- Category A: prescription only, single dispensing, tighter rules.
- Category B: prescription only, repeat dispensing possible.
- Category D: no prescription, expert advice at the point of sale.
- Category E: general retail, no specialist advice required.
The category drives your advertising options, so external providers clarify the expected category before submission rather than after approval.
Frequently asked questions
Can you use our EU dossier as it is?
Almost. The scientific modules travel well, but Switzerland needs its own application forms, its own product information in three languages, Swiss labelling and sometimes additional Swiss-specific documentation. External providers do that adaptation rather than sending you a list of gaps.
How many variations does a typical product generate per year?
For a mature product with an active EU life cycle, two to six Swiss filings per year is normal: safety updates from the EU label, CMC changes, a new pack size, artwork revisions. External providers include a variation budget in the quote so the yearly cost is predictable.
Who signs the submission?
The holder signs, which means the providers when external providers hold the authorisation. You approve the content in writing beforehand. For scientific content external providers do not overrule your experts; external providers make sure the file meets Swiss form and deadline requirements.
What happens if Swissmedic rejects a change?
External providers get a reasoned decision with an objection route. In most cases the issue is documentation rather than substance, and a corrected refiling resolves it. Where the substance is the problem, external providers tell you that plainly instead of billing a second attempt.
Enquire about Swiss MAH support
Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.
- Independent information portal
- Public Swiss sources, independent explanations, and enquiries about external specialist services.